ConVerd's Oncolytic Vaccinia Virus hV01 Completed First Patient Dosing in Its First Phase IIa Clinical Study

On April 15, 2025, the first Phase IIa clinical study of hV01, ConVerd's first oncolytic vaccinia virus product, successfully completed its first patient dosing, with the subject in good condition. This phase IIa clinical study investigates the administration of a single dose of recombinant human IL-21 oncolytic poxvirus injection (hV01) per cycle for the treatment of patients diagnosed with advanced sarcoma and cervical cancer. It is important to note that the indication is for advanced sarcoma and recurrent or metastatic cervical cancer for which there is no standard of care available at this stage of the treatment process or where standard of care has failed.

The PI in charge of the hV01’s first Phase IIa clinical study, Director Zhiquan Qin, currently the Chief Physician of Medical Oncology at Zhejiang Provincial People's Hospital, brings 30 years of clinical oncology experience, specializing in comprehensive treatments for lung cancer, primary liver cancer, gastrointestinal malignancies, breast cancer, and renal cancer, including chemotherapy, immunotherapy, and targeted therapy. He also serves as a committee member of the Multidisciplinary Diagnosis Working Group of the Tumor Marker Professional Committee, Chinese Anti-Cancer Association, and the Zhejiang Medical Doctor Association Oncology Branch.